Tao Wang

List of Publications by Year
in descending order

29 papers	1,564 citations	430442 18 h-index	476904 29 g-index
29 all docs	29 docs citations	29 times ranked	1266 citing authors

#	Article	IF	Citations
1	Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. Journal of Medicinal Chemistry, 2022, 65, 4058-4084.	2.9	1
2	The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 45-64.	0.8	1
3	Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis. Journal of Medicinal Chemistry, 2022, 65, 8948-8960.	2.9	6
4	Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis. ACS Medicinal Chemistry Letters, 2021, 12, 1413-1420.	1.3	3
5	Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. Medicinal Chemistry Research, 2021, 30, 1-26.	1.1	4
6	Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings. ACS Medicinal Chemistry Letters, 2021, 12, 1605-1612.	1.3	3
7	A survey of core replacements in indole-based HIV-1 attachment inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1423-1429.	1.0	16
8	Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties. Journal of Medicinal Chemistry, 2018, 61, 946-979.	2.9	19
9	Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Medicinal Chemistry Letters, 2018, 9, 89-93.	1.3	12
10	Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir. Journal of Medicinal Chemistry, 2018, 61, 62-80.	2.9	98
11	Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists. ACS Medicinal Chemistry Letters, 2018, 9, 17-22.	1.3	13
12	Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. Journal of Medicinal Chemistry, 2018, 61, 7168-7188.	2.9	22
13	Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir. Journal of Medicinal Chemistry, 2018, 61, 6308-6327.	2.9	34
14	Inhibitors of HIV-1 attachment. Part 10. The discovery and structureâ€“activity relationships of 4-azaindole cores. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 213-217.	1.0	29
15	In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. Antimicrobial Agents and Chemotherapy, 2012, 56, 3498-3507.	1.4	118
16	Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043). Journal of Medicinal Chemistry, 2012, 55, 2048-2056.	2.9	49
17	In VivoPatterns of Resistance to the HIV Attachment Inhibitor BMS-488043. Antimicrobial Agents and Chemotherapy, 2011, 55, 729-737.	1.4	47
18	Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. Virology, 2010, 402, 256-261.	1.1	19

#	Article	IF	Citations
19	Utilization of in vitro Cacoâ€2 permeability and liver microsomal halfâ€life screens in discovering BMSâ€488043, a novel HIVâ€1 attachment inhibitor with improved pharmacokinetic properties. Journal of Pharmaceutical Sciences, 2010, 99, 2135-2152.	1.6	15
20	Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1977-1981.	1.0	58
21	Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5140-5145.	1.0	49
22	Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 5. An Evolution from Indole to Azaindoles Leading to the Discovery of 1-(4-Benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a Drug Candidate That Demonstrates Antiviral Activity in HIV-1-Infected Subjects. Journal of Medicinal Chemistry, 2009, 52, 7778-7787.	2.9	98
23	An effective procedure for the preparation of 3-substituted-4- or 6-azaindoles from ortho-methyl nitro pyridines. Tetrahedron Letters, 2006, 47, 5653-5656.	0.7	22
24	Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events. Journal of Virology, 2006, 80, 4017-4025.	1.5	108
25	Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806):Â A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactionsâ€. Journal of Medicinal Chemistry, 2003, 46, 4236-4239.	2.9	206
26	A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11013-11018.	3.3	339
27	A General Method for the Preparation of 4- and 6-Azaindoles. Journal of Organic Chemistry, 2002, 67, 2345-2347.	1.7	66
28	An Effective Procedure for the Acylation of Azaindoles at C-3. Journal of Organic Chemistry, 2002, 67, 6226-6227.	1.7	51
29	The mono-functionalization of symmetrical polyamines. Tetrahedron, 2002, 58, 3111-3128.	1.0	58